Your missing links are here (8 January 2021)

Some of the best stuff we picked up around the internet

By: Gorm Palmgren - Jan. 8, 2021

Top Picks

Research

  • A new electrochemical microfluidic biosensor has improved detection of microRNAs (miRNAs) that are increasingly used for diagnostics. The new multiplexed CRISPR-Biosensor X divides the biochip's previous single channel into subsections allowing for the amplification-free and simultaneous quantification of up to eight miRNAs.
  • Phages are the principal target of the adaptive immune system, namely CRISPR, that bacteria and archaea developed as protection from foreign DNA. Studying the CRISPR-Cas spacers in Pseudomonas aeruginosa, researchers now confirm that the system also targets closely related prokaryotic species and that CRISPR acts as an important constraint to horizontal gene transfer.
  • Researchers have used CRISPR-Cas9 to quickly validate findings from genome-wide association studies (GWASs) that screen large populations for genetic variants linked to a disease or other phenotype. A GWAS study pointed to a putative enhancer element for the gene PRPF38A involved in bone cell formation. When CRISPR-Cas9 was used to delete this sequence, symptoms of a kind of osteoporosis were alleviated.
  • A new study sheds light on CRISPR-Cas9 editing dynamics in different conditions, including cell types and delivery methods. Among the results, the researchers find that the kinetics of AAV6-mediated homology-directed repair (HDR) deletions are inferior to non-homologous end-joining (NHEJ).

Industry

COVID-19

  • A new test for the rapid detection of Sars-CoV-2 specific RNA has been developed by Jennifer Doudna's lab and is posted on the medRxiv* server. The test is called DISCoVER (DiagnosticS with Coronavirus Enzymatic Reporting) and uses viral nucleic acid amplification and Cas13-mediated detection without RNA extraction.

Reviews and Roundups

Resources

Delivery

Heh, huh, wow

Tags

HashtagArticleHashtagMissing linksHashtagNews

CLINICAL TRIALS
Non-small Cell Lung Cancer,NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine